Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.42.
Several research analysts have commented on the stock. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of AzurRx BioPharma in a report on Wednesday, April 24th. ValuEngine raised shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. National Securities assumed coverage on shares of AzurRx BioPharma in a report on Tuesday, June 11th. They set a “buy” rating and a $9.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of AzurRx BioPharma in a research report on Wednesday.
Shares of AZRX traded down $0.03 during midday trading on Thursday, hitting $0.96. 63,500 shares of the company traded hands, compared to its average volume of 137,231. The firm has a 50 day simple moving average of $1.19. AzurRx BioPharma has a 52 week low of $0.86 and a 52 week high of $3.75. The stock has a market cap of $25.58 million, a PE ratio of -1.09 and a beta of 2.21.
Several hedge funds and other institutional investors have recently made changes to their positions in AZRX. Vanguard Group Inc. boosted its holdings in AzurRx BioPharma by 255.0% in the second quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after purchasing an additional 186,985 shares during the period. BlackRock Inc. boosted its holdings in AzurRx BioPharma by 57.6% in the second quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after purchasing an additional 15,463 shares during the period. JPMorgan Chase & Co. acquired a new position in AzurRx BioPharma in the second quarter worth $57,000. Regentatlantic Capital LLC acquired a new position in AzurRx BioPharma in the first quarter worth $48,000. Finally, Waldron Private Wealth LLC acquired a new position in AzurRx BioPharma in the first quarter worth $169,000. Hedge funds and other institutional investors own 10.59% of the company’s stock.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Further Reading: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.